Come work with us.

Aro Biotherapeutics is developing Centyrins, a patented platform technology based on fibronectin domains that combines antibody-like properties with small molecule characteristics. The company focuses on discovering and developing Centyrin-oligonucleotide conjugate therapies to enable targeted delivery of oligonucleotides to extra-hepatic tissues.